Orchestra BioMed Holdings, Inc.
OBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOrchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. Valued at $326.4M, OBIO is a small-cap name in its sector. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.
Market Cap
$326.4M
Beta
0.53
P/E (TTM)
—
P/E (Fwd)
-3.58
EPS (TTM)
$-0.84
EPS (Fwd)
$-1.52
ROE
-397.3%
ROA
-45.7%
Cash
$110.0M
Total Debt
$70.8M
Free CF
-$31.8M
52W Change
94.6%
Annual Financials
Cash vs Debt
Where OBIO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OBIO finished 17.58% above its 150-day moving average ($4.21) and 15.93% above its 200-day moving average ($4.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OBIO overbought or oversold?
At the September 3, 2026 close, OBIO's RSI(14) was 60.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Orchestra BioMed Holdings, Inc. holds $110.0M in cash against $70.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$31.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -397.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $3.5M to $33.5M.
The relatively low beta of 0.53 suggests OBIO is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OBIO.